Tesorai Raises $5.3 Million To Unlock Experimental Life Sciences Data

Tesorai has raised $5.3 million in seed financing to expand an AI platform that processes and harmonizes raw experimental data for life sciences research.

The round brings the company’s total funding to $8 million. Investors include Perplexity Fund, IQT, South Central Ventures, New Stack Ventures, NextGen Venture Partners, f7 Ventures, VitalStage Ventures, and ZAKA.

Tesorai plans to expand its work with biopharmaceutical companies and research organizations, develop partnerships across the life sciences tools sector, and extend its platform into additional types of molecular data.

Reprocessing Existing Research

Experimental data is frequently stored across public repositories, corporate databases, and institutional archives in inconsistent formats. Tesorai returns to the underlying raw data and reprocesses it so results from different studies can be searched and compared.

Tesorai Search processes raw experimental files in the cloud. Tesorai Chat allows scientists to conduct downstream analyses through conversational prompts, while Tesorai Trove enables researchers to compare findings with thousands of earlier studies.

The company said its patented model can process thousands of files and terabytes of data in hours rather than the months sometimes required by conventional workflows.

In one demonstration, Tesorai reprocessed raw files from five public brain studies and recovered p-tau217, a major Alzheimer’s disease marker that the original studies had not reported.

Its researchers have also reported that adding protein data enabled a relatively small single-cell AI model to match or outperform larger models trained solely on RNA data across several benchmarks.

Commercial And Research Expansion

Tesorai has signed contracts with biopharmaceutical and research organizations and collaborated with institutions including MD Anderson Cancer Center, New York University, and the Michael J. Fox Foundation.

The company was founded by former Google and Verily executives Melissa Miao, Peter Cimermancic, and Charlie Kim.

KEY QUOTES:

Life science R&D is accelerating and becoming increasingly autonomous, which makes it more important to extract as much insight as possible from every experiment. Tesorai does this for a lab’s new data and for thousands of published studies. The gains compound as each experiment builds on the last, and ultimately, this helps the industry develop better medicines and products, faster.

Charlie Kim, Co-Founder and Chief Scientific Officer of Tesorai

Every experiment produces far more data than its paper can report, and most of it is never revisited. Our platform reclaims the value of experiments that have already been done and amplifies each new experiment with the relevant evidence that already exists.

Melissa Miao, Co-Founder and CEO of Tesorai

The quality of data and metadata a model learns from can matter as much as the size of the dataset, and much of the data that biology’s AI models need has already been collected. Yet only a small fraction of it is readily accessible, harmonized, and usable today.

Peter Cimermancic, Co-Founder and Chief Technology Officer of Tesorai

AI has the potential to dramatically accelerate scientific research, but its impact will depend on access to high-quality experimental data. Tesorai is building the infrastructure to make that data usable at scale, giving scientists and AI systems a stronger foundation for advancing research.

Joanna Lee Shevelenko, Co-Founder and General Partner of Perplexity Fund

Labs are generating more experimental data than ever, but its full value depends on processing that data efficiently. Tesorai’s team has built AI that does that at scale, for the experiments labs run today and the thousands already sitting in public archives.

Tatjana Zabasu Mikuž, Managing Partner at South Central Ventures